User profiles for ANDREAS D. HARTKOPF

Andreas D. Hartkopf

Department of Women's Health, Tuebingen University
Verified email at med.uni-tuebingen.de
Cited by 5637

Early dissemination seeds metastasis in breast cancer

…, M Grauvogl, N Eichner, F Weber, AD Hartkopf… - Nature, 2016 - nature.com
Accumulating data suggest that metastatic dissemination often occurs early during tumour
formation, but the mechanisms of early metastatic spread have not yet been addressed. Here, …

Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer

…, AL Bouligny, A Jensen, A Osorio, AD Hartkopf… - JAMA …, 2017 - jamanetwork.com
Importance Cytotoxic CD8 + tumor-infiltrating lymphocytes (TILs) participate in immune control
of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8 + …

[HTML][HTML] Mutations in BRCA1/2 and other panel genes in patients with metastatic breast cancer—Association with patient and disease characteristics and effect on …

…, SY Brucker, A Schneeweiss, AD Hartkopf… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Among patients with metastatic breast cancer (mBC), the frequency of germline
mutations in cancer susceptibility genes and the clinical relevance of these mutations are …

[HTML][HTML] Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

A Hein, AD Hartkopf, J Emons, MP Lux, B Volz… - European journal of …, 2021 - Elsevier
… - original draft, review & editing, supervision, visualisation and project administration; Andreas
D. Hartkopf helped in resources, project administration, review & editing and investigation; …

Endocrine-resistant breast cancer: mechanisms and treatment

AD Hartkopf, EM Grischke, SY Brucker - Breast care, 2020 - karger.com
Background: Endocrine treatment is one of the most effective therapies for estrogen receptor-positive
breast cancer. However, most tumors will develop resistance to endocrine therapy …

Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

V Müller, N Nabieva, L Häberle, FA Taran, AD Hartkopf… - The Breast, 2018 - Elsevier
Objectives Improved progression-free survival is considered as treatment goal for patients
with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of …

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

…, C Cybulski, HR Harris, AD Hartkopf… - The Journal of …, 2018 - Wiley Online Library
We aimed to validate the prognostic association of p16 expression in ovarian high‐grade
serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein …

[HTML][HTML] Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients–results from a large single-centre analysis

AD Hartkopf, FA Taran, M Wallwiener, M Hahn… - European journal of …, 2014 - Elsevier
Background This is the largest single-centre study to determine the prognostic relevance of
disseminated tumour cells (DTCs) from the bone marrow (BM) of stage I-III breast cancer …

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors–Data from the German PRAEGNANT breast cancer …

AD Hartkopf, J Huober, B Volz, N Nabieva, FA Taran… - The Breast, 2018 - Elsevier
Purpose This study describes comprehensive data from a breast cancer registry concerning
the use of endocrine treatment (ET) and chemotherapy in the first, second and higher …

Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer

AD Hartkopf, P Wagner, D Wallwiener… - Anticancer …, 2011 - ar.iiarjournals.org
Background: The detection of >5 circulating tumor cells (CTCs)/7.5 ml blood in patients being
treated for metastatic breast cancer (MBC) has recently been shown to be predictive for …